Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus DECABID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus DECABID.
CLARINEX D 24 HOUR vs DECABID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
None Documented
None Documented
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination